دانلود کتاب راهنمای فشار خون بالا جامعه اروپایی
Manual of Hypertension of the European Society of Hypertension, 2ed

Contents

Chapter 1: EPIDEMIOLOGY OF HYPERTENSION
Chapter 2: THE TOTAL CARDIOVASCULAR RISK
Chapter 3: CLASSICAL AND NEW RISK FACTORS
Chapter 4: PULSE PRESSURE AS A CARDIOVASCULAR RISK FACTOR
Chapter 5: CLINICAL SIGNIFICANCE OF HIGH HEART RATE IN HYPERTENSION
Chapter 6: OBESITY AND OBSTRUCTIVE SLEEP APNEA
Chapter 7: DIABETES MELLITUS
Chapter 8: STRESS-RELATED, PSYCHOSOCIAL, AND OTHER RISK FACTORS IN THE HYPERTENSIVE PATIENT
Chapter 9: BLOOD PRESSURE VARIABILITY: METHODOLOGICAL ASPECTS, PHYSIOLOGY, AND CLINICAL IMPLICATIONS
Chapter 10: ANTIHYPERTENSIVE TREATMENT STRATEGIES
Chapter 11: HEMODYNAMICS OF HYPERTENSION
Chapter 12: GENETIC BASIS OF BLOOD PRESSURE AND HYPERTENSION
Chapter 13: STRUCTURAL CARDIOVASCULAR CHANGES IN HYPERTENSION
Chapter 14: IMPAIRED AUTONOMIC CARDIOVASCULAR CONTROL IN HYPERTENSION
Chapter 15: THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
Chapter 16: ETIOLOGICAL AND PATHOPHYSIOLOGICAL ASPECTS OF HYPERTENSION: OTHER HUMORAL-ENDOCRINE FACTORS
Chapter 17: CARDIAC DAMAGE AND PROGRESSION TO HEART FAILURE
Chapter 18: BRAIN DAMAGE
Chapter 19: LARGE ARTERY DAMAGE: MEASUREMENT AND CLINICAL IMPORTANCE
Chapter 20: SMALL ARTERY STRUCTURE AND FUNCTION IN HYPERTENSION
Chapter 21: ENDOTHELIAL DAMAGE: MEASUREMENT AND CLINICAL IMPORTANCE
Chapter 22: RENAL DAMAGE AND HYPERTENSION: MECHANISMS OF RENAL END-ORGAN DAMAGE
Chapter 23: RETINAL CHANGES IN HYPERTENSION
Chapter 24: BP MEASUREMENTS AND OTHER DIAGNOSTIC PROCEDURES
Chapter 25: BLOOD PRESSURE RESPONSE TO ACUTE PHYSICAL AND MENTAL STRESS
Chapter 26: CENTRAL BLOOD PRESSURE
Chapter 27: THE DIAGNOSTIC APPROACH IN UNCOMPLICATED AND COMPLICATED HYPERTENSION
Chapter 28: BLOOD PRESSURE TARGETS OF ANTIHYPERTENSIVE TREATMENT
Chapter 29: INTERVENTIONAL TRIALS IN HYPERTENSION: WHAT HAVE WE LEARNED AND WHAT REMAINS TO BE LEARNED?
Chapter 30 THE NEPHROPROTECTIVE EFFECT OF ANTIHYPERTENSIVE TREATMENT
Chapter 31: NONPHARMACOLOGICAL INTERVENTIONS
Chapter 32: MEDICAL TREATMENT OF HYPERTENSION: MONOTHERAPY AND COMBINATION THERAPY
Chapter 33: EMERGING ANTIHYPERTENSIVE DRUGS
Chapter 34: THE POLYPILL
Chapter 35: INVASIVE PROCEDURES
Chapter 36: CLINICAL MANAGEMENT OF PATIENTS PRESENTING WITH HYPERTENSION AND PERIPHERAL ARTERY DISEASE
Chapter 37: RESISTANT AND MALIGNANT HYPERTENSION
Chapter 38: HYPERTENSIVE EMERGENCIES AND URGENCIES
Chapter 39: SECONDARY HYPERTENSION: DIAGNOSIS AND TREATMENT
Chapter 40: HYPERTENSION IN DIABETES MELLITUS
Chapter 41: HYPERTENSION IN CHILDREN AND ADOLESCENTS
Chapter 42: HYPERTENSION IN PREGNANCY
Chapter 43: POSTTRANSPLANT HYPERTENSION
Chapter 44: HYPERTENSION IN PATIENTS WITH RENAL PARENCHYMAL DISEASE, CHRONIC RENAL FAILURE, AND CHRONIC DIALYSIS
Chapter 45: THE METABOLIC SYNDROME IN HYPERTENSION
Chapter 46: WHITE-COAT AND MASKED HYPERTENSION
Chapter 47: SECONDARY PREVENTION OF STROKE
Chapter 48: HYPERTENSION AND ATRIAL FIBRILLATION: MODERN EPIDEMIOLOGIC, PATHOPHYSIOLOGIC, AND THERAPEUTIC ASPECTS
Chapter 49: MANAGEMENT OF PERIOPERATIVE HYPERTENSION
Chapter 50: PHARMACOECONOMIC AND COST-BENEFIT ASPECTS
Chapter 51 HOW’ TO ORGANIZE AND RUN A HYPERTENSION CENTER
Chapter 52: BLOOD PRESSURE CONTROL IN EUROPE
Chapter 53: HYPERTENSION IN THE VERY ELDERLY
Chapter 54: HYPERTENSION IN ACUTE STROKE
Chapter 55: CARDIOVASCULAR RISK OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
Chapter 56: COMPLIANCE TO TREATMENT IN HYPERTENSION
Chapter 57: ANTIHYPERTENSIVE TREATMENT IN PATIENTS WITH HEART FAILURE
Chapter 58: RESIDUAL RISK AND RESISTANCE TO THE BENEFITS OF ANTIHYPERTENSIVE TREATMENT
Chapter 59: A COMMENTARY ON THE 2013 ESH/ESC GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION